Abstracts tagged "antiphospholipid antibodies and biomarkers"

Abstract Number: 1073 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results
Savino Sciascia¹, Rohan Willis², Vittorio Pengo³, Steven Krilis⁴, Danieli Andrade⁵, Doruk Erkan⁶, Maria Laura Bertolaccini⁷ and On Behalf of APS ACTION .⁸, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴Department of Immunology, Allergy and Infectious Diseases, University of New South Wales, Sydney, Australia, ⁵Rheumatology, University of Sao Paulo, Sao Paulo, Brazil, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁷Academic Department of Vascular Surgery, King’s College London, London, United Kingdom, ⁸., New York, NY
Background/Purpose: The APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].